TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05627375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Full-dose anticoagulant therapy (AC)
Description: Anticoagulant (AC) therapy: at the investigator's discretion in accordance with international recommendations for the management of DVT/PE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Full-dose anticoagulant therapy (AC)
Description: Anticoagulant (AC) therapy: at the investigator's discretion in accordance with international recommendations for the management of DVT/PE

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet therapy (AP)
Description: Aspirin (at a daily dose ≤100 mg) or Clopidogrel (at a daily dose ≤75mg)
Study: NCT06174623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ModulHeart Support
Description: The ModulHeart device will be implanted in the descending abdominal aorta.
Study: NCT06295939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: social support program
Description: Group 2, the experimental group, will receive routine nursing care from the assigned nurse and a social support program provided by the researcher, as follows:~Phase 1 (Before Pregnancy Termination)~Phase 2 (After Pregnancy Termination, Before Returning Home):

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine nursing care
Description: The sample group will receive routine nursing care from the assigned nurse.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine nursing care
Description: The sample group will receive routine nursing care from the assigned nurse.
Study: NCT05872802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eccentric exercises and electrical stimulation
Description: Eccentric exercises and strengthening currents to improve ankle dorsiflexion in professional padel players.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: proprioceptive neuromuscular facilitation
Description: proprioceptive neuromuscular facilitation to improve ankle dorsiflexion in professional padel players.
Study: NCT05449990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participation in PFCC-IR
Description: Patient-and-family-centered-care interdisciplinary rounds (PFCC-IR) with the critical care team are standard practice in the ICU but it doesn't usually include family members. The intervention for this study is PFCC-IR that include one family member of the patient.
Study: NCT06099899

Intervention type: OTHER
Intervention: interview
Description: conduct in-depth interviews

Intervention type: OTHER
Intervention: interview
Description: conduct in-depth interviews
Study: NCT06452966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional Chinese medicine
Description: patients in the group will receive one of or a combination of the following interventions:~Oral Chinese medicine decoction:~The Chinese medicine practitioner will personally examine the patient and judge the patient's condition through the four diagnostic methods of traditional Chinese medicine(TCM): sight, smell, inquiry, and incision. Based on the syndrome differentiation and treatment of the patient's condition, he or she will prescribe an oral Chinese herbal decoction, two to three times a day, for two weeks.~Acupuncture or low level laser acupuncture treatment:~Chinese medicine practitioners select acupuncture points for treatment based on the patient's condition and treat them twice a week for 20 minutes each time for a total of two weeks.~the intervantion depents on the TCM doctor decision based on the patient's diagnosis and needs.~in addition, the patients will recive ICU care and medication based on patient's needs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine ICU care
Description: Patients will receive ICU care

Intervention type: OTHER
Group type: OTHER
Intervention: historical Routine ICU care
Description: Patients had received ICU care
Study: NCT00535314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402 Dose1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402 Dose2
Study: NCT02712151

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal Wall Block
Description: bilateral TAP and RS blocks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal Wall Block
Description: bilateral TAP and RS blocks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical infiltration
Description: distributed between the 4 laparoscopic port sites.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical infiltration
Description: distributed between the 4 laparoscopic port sites.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterile saline
Description: Placebo injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sterile saline
Description: Placebo injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2%
Description: Ropivacaine 0.2% 1.0 ml/kg total in divided doses for bilateral TAP and RS blocks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: For nerve localization

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: For nerve localization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5%
Description: Ropivacaine 0.5% 0.4 ml/kg total in divided doses distributed between the 4 laparoscopic port sites
Study: NCT05273476

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: apically repositioned flap+ xenogeneic collagen matrix +free gingival graft
Description: Harvest a strip free gingival graft from the palate, then place it above apically repositioned flap and fix xenogeneic collagen matrix to the recipient bed
Study: NCT05586048

Intervention type: DRUG
Intervention: Yiqi Fumai Lyophilized Injection(YQFM)
Description: No intervention was involved, but patients will be divided into exposed or non-exposed groups based on whether they received YQFM
Study: NCT05235945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise intervention
Description: Described in arm descriptions
Study: NCT05472766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Direct Acting Oral Anticoagulant starting at Day 30
Description: Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Direct Acting Oral Anticoagulant starting at Day 90
Description: Dabigatran, Rivaroxaban, Apixaban or Edoxaban at standard dose as recommended by the MRP
Study: NCT05105464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1815
Description: Subjects will receive SYHA1815 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1815
Description: Subjects will receive SYHA1815 orally.
Study: NCT05945186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Pneumatic Compression (IPC)(Kendall SCD SmartFlow™ compression system with Cardinal Health Element compression sleeves)
Description: External intermittent pneumatic compression (IPC) systems are applied to subject legs and comprise of a controller, associated tubing set and single patient use disposable leg sleeves. The disposable sleeves are latex free and contain air bladder(s) that are inflated by the controller to provide compression to the legs/feet. These devices are designed to increase venous blood flow in at risk patients in order to help prevent Venous ThromboEmbolism (VTE), including Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).
Study: NCT05337787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flipped classroom approach
Description: The students in the experimental group were trained using the flipped learning model.
Study: NCT06504537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THERAGUN PERCUSSION THERAPY
Description: In Group A, Patients will receive Theragun Percussion therapy along with routine Physical Therapy Treatment. The range of motion of lateral flexion and forward flexion will take by using a bubble inclinometer. Then the patient will place in a sitting position with the shoulder area exposed. Percussion therapy by using the Theragun device will give by a specific order. Treatment will start with the percussion head applied at the origin and insertion heads of the trapezius, Rhomboid and scalene muscle for 3-4 minutes each. Following this the percussive Theragun applicator will applied with circular strokes along the length of the muscle for 3 minutes. The pressure of application will adjust to the subject's tolerance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMPRESSION THERAPY
Description: In Group B, Compression therapy will be administered to the patients by migraine relief gel cap for 25 minutes during migraine attacks. The cap will store in a freezer (15-18°C). At the onset of the migraine attacks, patients wore the cap and used it. We will choose 25 minutes as the time for application of the gel cap based on the results of two published studies.(23) Headache severity will measured by Visual Analogue Scale and pain relief will measured on a similar scale. Analgesic treatment will not take within 25 minutes after the onset of cold therapy. If patients did not experience adequate relief from the headache, we will allow them to use analgesics 25 minutes after the onset of cold therapy. The routine physical treatment will be same as in group A.
Study: NCT04996173

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spray cryotherapy
Description: A novel FDA cleared technique that allows for Liquid nitrogen (LN2) to be delivered in a metered fashion via a catheter through a flexible bronchoscope.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ballon Dilation
Description: An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3 to 9 atm) using a syringe and pressure manometer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ballon Dilation
Description: An endoscopic balloon that is inflated with water to pressures between 45 and 131 psi (3 to 9 atm) using a syringe and pressure manometer.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Radial Incision
Description: Carbon dioxide (CO2) laser or Monopolar electrocautery knife

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Incision
Description: Carbon dioxide (CO2) laser or Monopolar electrocautery knife
Study: NCT05126186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: haplo-SCT with PTCy
Description: Conditioning regimen Fludarabine (30mg/m2/day from day -6 to day -4), Cyclophosphamide (14.5 mg/kg/day at day -6 and day -5) except for patients who received a total dose of Cyclophosphamide \>100mg/Kg during the first Bone Marrow Transplantation Total Body Irradiation (2 Gray on day -1).~Source of stem cell source Peripheral blood stem cell Minimal target dose of 4.106 CD34+ cells/kg of recipient~GvHD prophylaxis Cyclophosphamide 50 mg/Kg/day at D+3 and D+4 Ciclosporine from day+5 (residual 200 à 300ng/l) Mycophenolate mofetyl at 15mg/Kg x2/day from day+5~Prevention of EBV reactivation Rituximab : 150mg/m2 intravenously at Day+5 post Haplo-SCT Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic.
Study: NCT06002399

Intervention type: DEVICE
Group type: OTHER
Intervention: cataract surgery
Description: cataract surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cataract surgery
Description: cataract surgery
Study: NCT05092542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Refugee and Immigrant Well-being Project (RIWP)
Description: 6-month mental health intervention that pairs university students with newcomers to engage in mutual learning, resource mobilization, and social change efforts
Study: NCT06048107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teniposide
Description: Teniposide is semisynthetic analogues of podophyllotoxin, and they are used in the treatment of leukemia, lymphoma, and certain sorts of solid tumors.In addition, tiniposide has central permeability and is commonly used in the treatment of central nervous system tumors.
Study: NCT06387173

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT04858750

Intervention type: DEVICE
Group type: OTHER
Intervention: Placement of ureteral D-J stent after ureteroscopic holmium laser lithotripsy
Description: During ureteral holmium laser lithotripsy operation, after the stones were fragmented, the D-J stents of three different types were placed, the insertion process are exactly the same.

Intervention type: DEVICE
Group type: OTHER
Intervention: Placement of ureteral D-J stent after ureteroscopic holmium laser lithotripsy
Description: During ureteral holmium laser lithotripsy operation, after the stones were fragmented, the D-J stents of three different types were placed, the insertion process are exactly the same.

Intervention type: DEVICE
Group type: OTHER
Intervention: Placement of ureteral D-J stent after ureteroscopic holmium laser lithotripsy
Description: During ureteral holmium laser lithotripsy operation, after the stones were fragmented, the D-J stents of three different types were placed, the insertion process are exactly the same.
Study: NCT05903729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental therapy treatment
Description: The group will receive NDT therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: conventional physiotherapy
Study: NCT05046847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3811
Description: TQB3811 is a second-generation TrkA inhibitor.
Study: NCT02213575

Intervention type: DRUG
Group type: OTHER
Intervention: Minocycline
Description: Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and week 12-24 follow-up MRI and PET scans for changes in the paraventricular nucleus.
Study: NCT05970874

Intervention type: DEVICE
Intervention: Hand grip strength measureme
Description: Hand grip strength (HSG) was measured in kg with the CAMRY Digital Hand Dynamometer (Model No. EH101, CAMRY).
Study: NCT05357443

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric bypass with transection of vagal nerves
Description: Vagal nerve interruption above the level of the stomach is a known treatment for complicated peptic ulcer disease. It is not commonly performed during routine gastric bypass. The vagi are, however, interrupted part-way down the stomach to create the gastric pouch. This is the pars flaccida technique.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Gastric bypass without transection of vagal nerves
Description: Dissection between the neurovascular bundle and the stomach, spareing the vagus nerves. This is the perigastric technique.
Study: NCT05656768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant Routine Protocol
Description: A constant routine protocol is used to directly examine markers of circadian rhythmicity (e.g., melatonin and core body temperature). A constant routine protocol requires an individual to remain in a dimly lit room, in a constant semi-recumbent posture, and remain awake for more than 24 hours. It is one of two gold-standard research protocols for examining circadian rhythms in humans.
Study: NCT05691998

Intervention type: OTHER
Intervention: Prosthetic foot questionnaire
Description: Prosthetic foot related questions will be asked to the patients
Study: NCT00992940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Sedation/Analgesia
Description: Patient controls delivery of sedation and analgesia requirements.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anesthetist-Controlled Sedation/Analgesia
Description: All sedation and analgesia requirements are determined and delivered by the attending anesthetist.
Study: NCT05498350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovulatory trigger timing
Description: Timing of medication to induce final oocyte maturation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovulatory trigger timing
Description: Timing of medication to induce final oocyte maturation
Study: NCT06443164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered Relief
Description: Pain Management Course that has been used to treat pain in patients with different pain conditions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Gender Affirming surgery without any attention to pain conditions prior to surgery.
Study: NCT05554484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood-derived tolerogenic dendritic cells
Description: AMI-DC, autologous dendritic cell product Inject 7.5 x 106 cells hypodermically to 1\~4 sites in the left axillary lymph node between 5-7 days after PCI and 12-14 days after PCI. . The administration must be done within 30 minutes after fully liquified.
Study: NCT05114395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Telerehabilitation Program
Description: See experimental and active comparator arms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Face-to-Face Program
Description: See experimental and active comparator arms.
Study: NCT05610904

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Prediction model evaluation
Description: a machine learning based anastomotic leakage prediction model
Study: NCT04688151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Dose level 1:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO once every day Durvalumab 1500mg infusion once every 4 weeks Dose level 2:Rituximab 375mg/m2 infusion once every 4 weeks for 8 cycles Acalabrutinib 100mg PO twice every day Durvalumab 1500mg infusion once every 4 weeks Expansion:Determined by the result of the dose escalation phase
Study: NCT06311045

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Description: Participants will take two NAC 600mg capsules daily for four weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will take two placebo 600mg capsules daily for four weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP) Therapy
Description: All participants will receive PAP therapy per standard of care for OSA.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP) Therapy
Description: All participants will receive PAP therapy per standard of care for OSA.
Study: NCT06037551

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measuremen subject
Description: measurement of the blood glucose concentration of subject using BGM and capillary finger tip blood

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measuremen reference
Description: measurement of the blood glucose concentration of subject using reference method and capillary finger tip blood
Study: NCT06299657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMPROVE
Description: IMPROVE is an individual manualized intervention.~Session1 includes:~* psychoeducation focusing on anxiety, its role in contributing to substance use, and the maintaining role of fear of bodily sensations~* guided discussion of maladaptive thoughts about bodily sensations related to anxiety~* how to challenge bodily sensations cognitively~* generating three takeaways about the benign nature of anxiety~Session 2 includes:~* review of homework~* psychoeducation focusing on the role of uncertainty in anxiety and identifying how new information can inform beliefs about uncertainty.~* when to challenge thoughts related to uncertainty and when to use acceptance regarding uncertainty.~Session 3 includes:~* review interoceptive exposure (IE) and behavioral exercises (BE) for progress~* revisit beliefs related to cognitive biases~* discuss areas where skills can be used moving forward

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PHET
Description: Clinicians will administer PHET using a Powerpoint presentation focused on healthy living habits, including healthy eating, water consumption, and sleep hygiene. Clinicians will guide participants through an exercise using the USDA food tracker to plan, record, and monitor nutritional information of meals. PHET also includes a digital program that will include EDUCATION, MY CURRENT MOOD, and BEHAVIORAL ACTIVITY tabs.
Study: NCT05993936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile application
Description: A mobile application developed by researchers for the problems experienced in the postpartum period and downloaded from the play store.
Study: NCT05362422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: long-term paired associative stimulation
Description: Paired associative stimulation (PAS) administered 3-5 times per week for 4 weeks to upper limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham long-term paired associative stimulation
Description: Sham transcranial magnetic stimulation and sham peripheral nerve stimulation.
Study: NCT06354582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C Injection
Description: Drug Specification: 5ml: 1g. Method: parturients in each group will be intravenously injected with corresponding dose after receiving epidural labor analgesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C Injection
Description: Drug Specification: 5ml: 1g. Method: parturients in each group will be intravenously injected with corresponding dose after receiving epidural labor analgesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C Injection
Description: Drug Specification: 5ml: 1g. Method: parturients in each group will be intravenously injected with corresponding dose after receiving epidural labor analgesia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The placebo comparator will receive normal saline with the same volume and be administered after the induction of epidural labor anesthesia.
Study: NCT05414981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-H3733
Description: 25 mg or 100 mg tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 mg or 100 mg tablets for oral administration
Study: NCT05837156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heptaflurane combined Cyclophenol
Description: Heptaflurane combined Cyclophenol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heptaflurane
Description: Heptaflurane only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophenol
Description: Cyclophenol only